Truist Securities Maintains Buy on Evolent Health, Lowers Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $16 to $10.